Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia
Tommaso Balestra(Children's Hospital of Philadelphia), Sarah K. Tasian(Children's Hospital of Philadelphia)
Cited by 5
Related Papers
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
|Blood|2016|163
Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL
|Journal of Clinical Investigation|2020|58